Startseite>>TED-347

TED-347

Katalog-Nr.GC39540

TED-347 ist ein potenter, irreversibler, kovalenter und allosterischer Inhibitor der YAP-TEAD-Protein-Protein-Wechselwirkung mit einem EC50-Wert von 5,9 μM fÜr die TEAD4⋅Yap1-Protein-Protein-Wechselwirkung. TED-347 bindet spezifisch und kovalent an Cys-367 innerhalb der zentralen Tasche von TEAD4 mit einem Ki von 10,3 μM. TED-347 blockiert die TranskriptionsaktivitÄt von TEAD und hat eine AntitumoraktivitÄt.

Products are for research use only. Not for human use. We do not sell to patients.

TED-347 Chemische Struktur

Cas No.: 2378626-29-8

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
102,00 $
Auf Lager
1mg
93,00 $
Auf Lager
5mg
121,00 $
Auf Lager
10mg
204,00 $
Auf Lager
25mg
417,00 $
Auf Lager
50mg
705,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with an EC50 of 5.9 μM for TEAD4⋅Yap1 protein-protein interaction. TED-347 specifically and covalently bonds with Cys-367 within the central pocket of TEAD4 with a Ki of 10.3 μM. TED-347 blocks TEAD transcriptional activity and has antitumor activity[1].

[1]. Khuchtumur Bum-Erdene, et al. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction. Cell Chem Biol. 2019 Mar 21;26(3):378-389.e13.

Bewertungen

Review for TED-347

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TED-347

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.